<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ENTECAVIR</span><br/>(en-te'ca-vir)<br/><span class="topboxtradename">Baraclude<br/></span><b>Classifications:</b> <span class="classification">antiviral agent</span>; <span class="classification">purine antimetabolite</span><br/><b>Prototype: </b>Lamivudine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 and 1 mg tablets; 0.05 mg/mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits hepatitis B viral (HBV) DNA polymerase by inhibiting viral reverse transcriptase of messenger RNA that ultimately
         results in inhibiting the synthesis of HBV DNA. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The antiviral activity of entecavir inhibits HBV DNA synthesis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of chronic hepatitis B infection in patients who have shown resistance to lamivudine or in nucleoside-treatment-naïve
         patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to entecavir; lactation; safety and effectiveness in pediatric patients 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Liver transplant patients; concurrent use of cyclosporine; renal impairment, ESRF, dialysis; pregnancy (category C), labor,
         and delivery. 
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Hepatitis B (nucleoside-treatmentnaïve patients)</span><br/><span class="rdage">Adult/Adolescent <img src="../images/special/greaterorequal.gif"/>16 y:</span> <span class="rdroute">PO</span> 0.5 mg qd<br/><br/><span class="indicationtitle">Chronic Hepatitis B (lamivudine-resistant patients)</span><br/><span class="rdage">Adult/Adolescent <img src="../images/special/greaterorequal.gif"/>16 y:</span> <span class="rdroute">PO</span> 1 mg qd<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cr<sub>Cl</sub> 3049 mL/min: decrease dose by 50%<br/>Cr<sub>Cl</sub> 1029 mL/min: decrease dose by 70%<br/>Cr<sub>Cl</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach (at least 2 h before/after a meal).</li>
<li>Administer after hemodialysis.</li>
<li>Dosage adjustment is recommended with creatinine clearance 
         </li><li>Store in a tightly closed container at 15°30° C (59°86° F)</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, fatigue, headache, insomnia, somnolence. <span class="typehead">GI:</span> Diarrhea, dyspepsia, nausea, vomiting. <span class="typehead">Metabolic:</span> Elevated liver enzymes (ALT, AST), hyperamylasemia, elevated lipase concentration, hyperbilirubinemia, fasting hyperglycemia,
      glycosuria, hematuria, <span class="speceff-life">lactic acidosis</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Coadministration of entecavir with drugs that reduce renal function or compete for active tubular secretion may increase serum
      concentrations of entecavir or the co-administered drug.<b></b>
<span class="typehead">Food:</span> High-fat meal reduces oral absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 0.51 h. <span class="typehead">Distribution:</span> 13% protein bound. <span class="typehead">Metabolism:</span> Minimal. <span class="typehead">Elimination:</span> Primarily eliminated in the urine. <span class="typehead">Half-Life:</span> 128149 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>	Monitor closely for adverse reactions when drugs that are known to affect renal function are taken concurrently.</li>
<li>	Lab tests: Periodic LFTs; monitor hepatic function for several months after drug is D/C; periodic fasting plasma glucose.</li>
<li>	Monitor for S&amp;S of lactic acidosis, including respiratory distress, tachycardia, and irregular HR.</li>
</ul>
<p><span class="adeffecttitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Follow directions for taking the drug (see <small>ADMINISTRATION</small>).
         </li>
<li>	Do not discontinue medication without consent of physician.</li>
<li>	Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>	Inform physician if you are or plan to become pregnant.</li>
<li>	Report any of the following to a health care provider: unexplained tiredness or weakness, unusual muscle pain, difficulty
            breathing, cold extremities, dizziness or light-headedness, irregular heartbeat, loss of appetite, stomach pain, nausea, vomiting,
            clay-colored stool, dark urine, or jaundice.
         </li>
<li>	Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>